For example, DT2216, a selective BCL-xL degrader, taking advantage of differential expression of Von Hippel Lindau E3 ligase [47], demonstrated antitumor activity with minimal effect on platelets providing hope for a reduction of thrombocytopenia in patients. The gene discussed is BCL2L1; the disease is Thrombocytopenia.